Publication:
Prognostic significance of mucinous histology in metastatic colorectal cancer patients treated with regorafenib

Simple item page
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorDEMİRCAN, NAZIM CAN
dc.contributor.authorYAŞAR, ALPER
dc.contributor.authorSEVER, NADİYE
dc.contributor.authorÇELİKEL, ÇİĞDEM
dc.contributor.authorSARI, MURAT
dc.contributor.authorKÖSTEK, OSMAN
dc.contributor.authorBAYOĞLU, İBRAHİM VEDAT
dc.contributor.authorsARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., Çelebi A., Majidova N., Sever N., ÇELİKEL Ç., et al.
dc.date.accessioned2023-09-12T05:32:11Z
dc.date.available2023-09-12T05:32:11Z
dc.date.issued2023-01-01
dc.description.abstractObjective: Prognostic factors for regorafenib therapy have not been fully defined. Mucinous adenocarcinoma (MAC) is a dis-tinct subtype of colorectal cancer (CRC). We investigated the significance of mucinous histology in patients treated with regorafenib for metastatic CRC (mCRC). Material and Methods: In this retrospective study, patients were stratified according to the presence of mucinous histology; >1% extracellular mucin was defined as mucinous component adenocarcinoma (MCAC), and containing no mucin was defined as non-MAC. The prognostic significance of mucinous histology for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Results: A total of 103 patients were included, including 20 (19.4%) patients with MCAC and 83 (80.6%) patients with non-MAC. The median follow-up time was 8.6 months (range 1.8-31.6 months). The median PFS was lower in cases with MCAC than those with non-MAC (3.2 months vs. 3.6 months, respectively, p=0.01). Median OS was lower in MCAC patients than in non-MAC patients (4.3 months vs. 9.6 months, respectively, p=0.008). In multivariate analyses, mucinous histology was an independent risk factor [haz-ard ratio (HR): 2.2, p=0.003] for PFS and Eastern Cooperative Oncology Group-Performance Status (HR: 2.2, p=0.01), cancer antigen 19-9 (HR: 1.7, p=0.03), and mucinous histology (HR: 1.9, p=0.02) were independent risk factors for OS. Conclusion: This study revealed the prognostic value of mucinous histology in mCRC patients treated with regorafenib. Consideration of histologic features may be helpful in se-lecting patients for regorafenib therapy.
dc.identifier.citationARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., Çelebi A., Majidova N., Sever N., ÇELİKEL Ç., et al., "Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib", Journal of Oncological Science, cilt.9, sa.2, ss.53-61, 2023
dc.identifier.doi10.37047/jos.2022-94250
dc.identifier.endpage61
dc.identifier.issn2651-4532
dc.identifier.issue2
dc.identifier.startpage53
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/151d993c-33fd-4c3c-b284-e2b958183165/file
dc.identifier.urihttps://hdl.handle.net/11424/293159
dc.identifier.volume9
dc.language.isoeng
dc.relation.ispartofJournal of Oncological Science
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectONCOLOGY
dc.subjectcolorectal neoplasms
dc.subjectMucinous adenocarcinoma
dc.subjectprognosis
dc.subjectregorafenib
dc.subjectMucinous adenocarcinoma
dc.subjectcolorectal neoplasms
dc.subjectregorafenib
dc.subjectprognosis
dc.titlePrognostic significance of mucinous histology in metastatic colorectal cancer patients treated with regorafenib
dc.typearticle
dspace.entity.typePublication
local.avesis.id151d993c-33fd-4c3c-b284-e2b958183165
local.indexed.atSCOPUS
relation.isAuthorOfPublicatione0cf127c-43d5-408a-af02-35ac7c3b544d
relation.isAuthorOfPublication8471e450-fb45-4e21-ab29-49db25acbf9a
relation.isAuthorOfPublication07d1c222-7e64-4fc6-8209-f298a813cc88
relation.isAuthorOfPublication6b4118fa-7c40-4624-8d36-2f74546b0e2c
relation.isAuthorOfPublicationbc2327ed-471c-42da-86dd-cef77979cda2
relation.isAuthorOfPublication0bbf9e5a-bf3e-4645-9f2d-1e1de92915d0
relation.isAuthorOfPublication45c34df1-af1e-4065-bd94-a363edfac03a
relation.isAuthorOfPublicationd4f139e7-cf36-415c-a82e-a9c7956ecede
relation.isAuthorOfPublication.latestForDiscoverye0cf127c-43d5-408a-af02-35ac7c3b544d

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13.pdf
Size:
812.26 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs